<p>This study evaluates integrated genomic models of response to immune checkpoint blockade for lung cancer patients. A computationally adjusted tumor mutation burden was combined with HLA class I genetic variation, mutational smoking signature and activating mutations in receptor tyrosine kinase genes to generate a prognostic classifier that outperforms tumor mutation burden.</p>

Genomic Determinants of Response to Immunotherapy

Carcinoma, Non-Small-Cell Lung study with WXS data on dbGaP (36 participants)

Genomic Determinants of Response to Immunotherapy

Description

Applying For Access

Summary